Steven AR Murphy: The Risk of Pulmonary Embolism in IV Stem Cell Therapy
Steven AR Murphy, Medical Director at Concierge Medical Associates, reposted from World Mitochondria Society on LinkedIn:
“IV infusion of mesenchymal stem cells resulting in mitochondrial aggregation and pulmonary embolism! That is the risk of IV stem cell therapy. World Mitochondria Society highlights this REAL risk. Concierge Medical Associates and I work with teams all over the globe to educate about the potential of mitochondrial transfer and about the risks of PE from these therapies. I’m so glad the science is being presented in Germany! We need a meeting in the USA now before we see some seriously Wild West risks and poor outcomes! p.s. that autologous MSC or PRP you received, that’s a mitochondrial transfer….”
Quoting World Mitochondria Society‘s post:
“Development of Mitochondria-Based Therapeutic Strategies for Disease Treatment. Prof. Kosuke Kusamori (Tokyo University of Science, Japan) presented innovative research advancing the field of mitochondrial transplantation and organelle-based therapy. His team investigated the use of mitochondria isolated from mesenchymal stromal cells (C3H10T1/2) as bioenergetic therapeutics capable of restoring damaged tissues. These mitochondria demonstrated strong antioxidant, proliferative, and cytoprotective properties, particularly in models of acute liver injury.
However, Prof. Kusamori identified a critical barrier to clinical translation: mitochondrial aggregation following systemic administration, which can cause pulmonary embolism. His group developed a proprietary anti-aggregation modification, allowing for safe intravenous delivery, targeted accumulation in the liver, and significant reduction of hepatic injury markers (ALT, AST).
This breakthrough demonstrates that controlling the physicochemical properties of isolated mitochondria is essential to unlock their therapeutic potential, a decisive step toward safe and effective mitochondria-based treatments for inflammatory and ischemic diseases.
Thanks for these excellent study.”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS